Fingolimod Hydrochloride
(KKGQTZUTZRNORY-UHFFFAOYSA-N)
Structure
- SMILES
- CCCCCCCCc1ccc(cc1)CCC(CO)(CO)N
- Molecular Formula:
- C19H33NO2
- Molecular Weight:
- 307.471
- Log P:
- 3.9046
- Hydrogen Bond Acceptor:
- 3
- Hydrogen Bond Donor:
- 3
- TPSA:
- 66.48
- CAS Number(s):
- 162359-55-9
Synonym(s)
1.
Fingolimod Hydrochloride
2.
2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride
3.
FTY 720
4.
FTY-720
5.
FTY720
6.
Fingolimod
7.
Gilenia
8.
Gilenya
9.
Hydrochloride, Fingolimod
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Chest Pain | FAERS: 3 | US FAERS | |
| 2 | Lymphopenia | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 3 | Bradycardia | FAERS: 2 | US FAERS | |
| 4 | Meningitis | FAERS: 2 | US FAERS | |
| 5 | Abdominal Pain | FAERS: 1 | US FAERS | |
| 6 | Alanine Aminotransferase Increased | FAERS: 1 | US FAERS | |
| 7 | Cervical dysplasia | FAERS: 1 | US FAERS | |
| 8 | Chest discomfort | FAERS: 1 | US FAERS | |
| 9 | Combined immunodeficiency | FAERS: 1 | US FAERS | |
| 10 | Delirium | FAERS: 1 | US FAERS | |
| 11 | Facial Paresis | FAERS: 1 | US FAERS | |
| 12 | Gastroenteritis | FAERS: 1 | US FAERS | |
| 13 | Headache | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 14 | Infection reactivation | FAERS: 1 | US FAERS | |
| 15 | Lower motor neurone lesion | FAERS: 1 | US FAERS | |
| 16 | Lymphoma | FAERS: 1 | US FAERS | |
| 17 | Multiple Sclerosis | FAERS: 1 | US FAERS | |
| 18 | Multiple sclerosis relapse | FAERS: 1 | US FAERS | |
| 19 | Myelitis | FAERS: 1 | US FAERS | |
| 20 | Oropharyngeal pain | FAERS: 1 | US FAERS | |
| 21 | Peripheral nerve palsy | FAERS: 1 | US FAERS | |
| 22 | Squamous cell carcinoma of skin | FAERS: 1 | US FAERS | |
| 23 | Varicella Zoster Virus Infection | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 24 | Wheelchair user | FAERS: 1 | US FAERS | |
| 25 | Aphasia | Canada Vigilance: 1 | Canada Vigilance | |
| 26 | Cerebral Infarction | Canada Vigilance: 1 | Canada Vigilance | |
| 27 | Concomitant disease aggravated | Canada Vigilance: 1 | Canada Vigilance | |
| 28 | Encephalitis | Canada Vigilance: 1 | Canada Vigilance | |
| 29 | Epilepsy | Canada Vigilance: 1 | Canada Vigilance | |
| 30 | Hemiparesis | Canada Vigilance: 1 | Canada Vigilance | |
| 31 | Lymphocyte count decreased | Canada Vigilance: 1 | Canada Vigilance | |
| 32 | Mental status changes | Canada Vigilance: 1 | Canada Vigilance | |
| 33 | Stupor | Canada Vigilance: 1 | Canada Vigilance | |
| 34 | Vasculitis | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.